Drug
Cisplatin, Docetaxel
Cisplatin, Docetaxel is a pharmaceutical drug with 4 clinical trials. Historical success rate of 66.7%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
66.7%
Based on 2 completed trials
Completion Rate
67%(2/3)
Active Trials
0(0%)
Results Posted
50%(1 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_3
3
75%
Ph phase_2
1
25%
Phase Distribution
0
Early Stage
1
Mid Stage
3
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
3(75.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
66.7%
2 of 3 finished
Non-Completion Rate
33.3%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Terminated(1)
Other(1)
Detailed Status
Completed2
Suspended1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
66.7%
Most Advanced
Phase 3
Trials by Phase
Phase 21 (25.0%)
Phase 33 (75.0%)
Trials by Status
completed250%
suspended125%
terminated125%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_3
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma
NCT00617656
suspendedphase_2
Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer
NCT01356303
completedphase_3
Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)
NCT00771563
completedphase_3
Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
NCT00622349
Clinical Trials (4)
Showing 4 of 4 trials
NCT00617656Phase 3
Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With Advanced Lung Carcinoma
NCT01356303Phase 2
Docetaxel Combined With Cisplatin as First Line in Patients With Metastatic Non-small Cell Lung Cancer
NCT00771563Phase 3
Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES)
NCT00622349Phase 3
Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4